Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination therapy** involving **mifepristone** and an **antidepressant**. Mifepristone is a synthetic steroid and a potent antagonist of the **glucocorticoid receptor** and **progesterone receptor**. While primarily approved and known for terminating pregnancy, it has also been studied for rapid treatment of **psychotic major depression**, especially in patients with elevated cortisol and poor response to conventional drugs[1][2][4][5]. Antidepressants, most commonly **selective serotonin reuptake inhibitors (SSRIs)**, are a diverse class of drugs whose members enhance serotonergic neurotransmission in the brain, primarily by inhibiting the serotonin transporter. In psychiatric research, mifepristone has been used adjunctively with antidepressants to achieve more rapid and robust reduction in psychotic and depressive symptoms in major depressive disorder with psychotic features[1][4][5]. No unique fixed-dose combination product is marketed under this name; rather, the combination refers to **concurrent use of mifepristone and an antidepressant** as part of a clinical regimen.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mifepristone + antidepressant.